#	Pagina
attuale pagina	/open-h2020/projects/201682/index.html

Opendata, web and dolomites

SynBioGABA

A new biosynthesis procedure for pharmaceutically active gamma-aminobutyric acids

Total Cost €

EC-Contrib. €

Partnership

Views

SynBioGABA project word cloud

Explore the words cloud of the SynBioGABA project. It provides you a very rough idea of what is the project "SynBioGABA" about.

poc enzyme style performance sustainability industrial chiral abundantly ip ultimately broadly license aminobutyric demonstration commercially generics incorporation provides pharmaceutical gabas producing population decades market treatment economics procedure grant advantages assembled western position attractive antidepressants drugs extensive pain portfolio synthesis poelarends consumers enantioselective prescribed efficient huge commercialization prof active gamma variety starting anticonvulsants strategies neuropathic companies erc hope acids coming pharmaceutically

Project "SynBioGABA" data sheet

The following table provides information about the project.

Coordinator	RIJKSUNIVERSITEIT GRONINGEN Organization address address: Broerstraat 5 city: GRONINGEN postcode: 9712CP website: www.rug.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2015-PoC
Funding Scheme	ERC-POC
Starting year	2016
Duration (year-month-day)	from 2016-07-01 to 2017-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	RIJKSUNIVERSITEIT GRONINGEN RIJKSUNIVERSITEIT GRONINGEN Organization address address: Broerstraat 5 city: GRONINGEN postcode: 9712CP website: www.rug.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (GRONINGEN)	coordinator	150˙000.00

Map

Project objective

Chiral γ-aminobutyric acids (GABAs) represent abundantly prescribed drugs, which are broadly applied as anticonvulsants, antidepressants and for the treatment of neuropathic pain. With the incorporation of more population to western-based style in the coming decades, there is a need of developing and producing pharmaceutically active GABAs and similar (or generic) drugs for higher number of consumers. Supported by an ERC starting grant, Prof. Poelarends has developed an efficient, enzyme-based procedure for the enantioselective synthesis of a wide variety of GABAs. The PoC grant will allow Prof. Poelarends to identify those opportunities in the huge pharmaceutical/generics market where his novel synthesis procedure for pharmaceutically active GABAs provides unique advantages over existing industrial synthesis strategies, in terms of performance, sustainability and economics. To enable the next step towards commercialization, a strong and commercially attractive IP position will be built and a portfolio will be assembled in which the performance of the new technology is compared to current industrial production strategies using extensive market research and demonstration studies. Ultimately, the hope is to license our technology to existing pharmaceutical/generics companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNBIOGABA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYNBIOGABA" are provided by the European Opendata Portal: CORDIS opendata.